In case you missed any, below is a recap of the episodes of OncLive On Air® that aired in January 2026. Check out our podcast page for a full episode lineup and to stay up to date with all the latest releases!
Experts Explore Intersections Between Breast Surgery and Radiation for Comprehensive Care: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD, PhD; and Valentina Bonev, MD, DABS, FACS, FSSO
In this episode of Precision and Progress: Radiotherapy in Oncology, Hirsch Matani, MD, and Elizabeth Zhang-Velten, MD, PhD, co-hosted a discussion with Valentina Bonev, MD, DABS, FACS, FSSO, about the interplay between surgery and radiation in breast cancer care. The experts highlighted the ongoing shift toward individualized, de-escalated breast cancer management that is aimed at maximizing outcomes and minimizing complications. They explained that patients with early-stage cancer often choose between a lumpectomy, which preserves breast tissue, or a mastectomy. They noted that lumpectomy typically requires follow-up radiation, whereas a mastectomy usually omits radiation unless the pathology reveals aggressive features or nodal involvement. To guide radiation targeting, Dr Bonev emphasized the importance of placing hemoclips in the lumpectomy cavity. These permanent markers help radiation oncologists pinpoint the "boost" dose, assist surgeons if margins need re-excision, and clarify future imaging by distinguishing scar tissue from recurrence, she noted.
PRRT With 177Lu-Edotreotide Improves Outcomes vs Everolimus in Metastatic GEP-NETs: With Jonathan R. Strosberg, MD
In this episode, Jonathan R. Strosberg, MD, a professor and leader in the Neuroendocrine Tumor Division and the Department of Gastrointestinal Oncology Research Program at Moffitt Cancer Center in Tampa, Florida, who reviewed the clinical implications of peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide (ITM-11) for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), drawing on efficacy and safety findings from the phase 3 COMPETE trial (NCT03049189). Dr Strosberg contextualized 177Lu-edotreotide as a PRRT approach that is mechanistically similar to lutetium Lu 177 dotatate (Lutathera) but uses a different somatostatin analog vector. He also emphasized the relevance of COMPETE as a head-to-head comparison of lutetium-based PRRT vs everolimus (Afinitor) in this setting.
FDA Approval Insights: BVd for Relapsed/Refractory Multiple Myeloma: With Surbhi Sidana, MD
In this episode, the discussion features Surbhi Sidana, MD, an associate professor of medicine (blood and marrow transplantation and cellular therapy) and leader of the Myeloma CAR-T/Immunotherapy Program at Stanford University/Stanford Medicine, as well as a member of the Stanford Cancer Institute, who provided clinical and regulatory perspectives on the FDA approval of belantamab mafodotin-blmf (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least 2 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. The approval was supported by findings from the phase 3 DREAMM-7 trial (NCT04246047). In this discussion, Dr Sidana reviewed the clinical rationale and study design underlying DREAMM-7, summarized the key efficacy and safety outcomes informing the BVd label, and discussed practical considerations for incorporating a belantamab mafodotin–based regimen into real-world treatment sequencing.
FDA Approval Insights: Epcoritamab Plus Rituximab/Lenalidomide for Relapsed/Refractory Follicular Lymphoma: With Lorenzo Falchi, MD
In this episode, the discussion features Lorenzo Falchi, MD, a medical oncologist/hematologist and assistant attending physician in the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, New York, who provided clinical and regulatory perspectives on the FDA approval of epcoritamab-bysp (Epkinly) in combination with rituximab (Rituxan) and lenalidomide (Revlimid) for relapsed/refractory follicular lymphoma after at least 2 prior lines of therapy. The approval was supported by primary results from the randomized phase 3 EPCORE FL-1 trial (NCT05409066). Dr Falchi discussed why this approval is clinically meaningful, establishing a chemotherapy-free triplet that significantly improves outcomes over the long-standing rituximab/lenalidomide backbone in the second-line setting and beyond—and reviewed practical considerations that inform real-world uptake of the regimen, including outpatient administration feasibility and mitigation of bispecific antibody–associated toxicities, such as cytokine release syndrome.
Emerging CELMoDs Set New Standards for Efficacy and Tolerability in Myeloma: With Rahul Banerjee, MD, FACP
In this episode, we had the pleasure of speaking with Rahul Banerjee, MD, FACP, about the ongoing investigation of CELMoDs for multiple myeloma. Dr Banerjee is an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Center, as well as an assistant professor in the Division of Hematology and Oncology at the University of Washington in Seattle. In the discussion, Dr Banerjee outlined the potential of CELMoDs for multiple myeloma management, highlighting their superior efficacy and safety compared with traditional immunomodulatory drugs (IMiDs) like lenalidomide (Revlimid) and pomalidomide (Pomalyst). He also noted strong preclinical and clinical data with CELMoDs, as well as their favorable safety profiles that include fewer immune and hematopoietic effects. Additionally, he explained that early data suggest that CELMoDs could replace traditional IMiDs, offering better long-term outcomes and fewer adverse effects.
Lisaftoclax Plus Azacitidine May Make New Inroads in Higher-Risk MDS Management: With Guillermo Garcia-Manero, MD
In today’s episode, the discussion features Guillermo Garcia-Manero, MD, who reviewed the clinical rationale for targeting BCL-2 in higher-risk myelodysplastic syndrome (MDS) and outlined the phase 3 GLORA-4 trial (NCT06641414) evaluating lisaftoclax (APG-2575) plus azacitidine (Vidaza) in this population. Dr Garcia-Manero is the chair ad interim in the Department of Leukemia in the Division of Cancer Medicine, as well as leader of the MDS/AML Moon Shot Program, at The University of Texas MD Anderson Cancer Center in Houston. Dr Garcia-Manero contextualized lisaftoclax as a next-generation BCL-2 inhibitor being advanced as a hypomethylating agent (HMA) partner strategy intended to improve on outcomes historically achieved with azacitidine alone in higher-risk MDS. He emphasized that GLORA-4 is designed as a registrational, randomized trial to rigorously assess whether adding BCL-2 inhibition to standard HMAs can meaningfully deepen responses and translate into clinically relevant benefit. He also characterized the regimen’s tolerability profile in a population that often requires careful supportive care and dose management.
How Community Oncology Experience Built the Foundation for a Dedicated Phase 1 Research Program: With D. Ross Camidge, MD, PhD; and Justin Call, MD
In this episode, Dr Camidge sat down with Justin Call, MD. Dr Call is a medical oncologist and hematologist at Utah Cancer Specialists in South Jordan. Dr Call explained that he has taken a unique professional path, transitioning from practicing as a general community oncologist to becoming a full-time phase 1 principal investigator within a community practice setting. He explained that he grew up in Salt Lake City, Utah, in a family of educators and accountants, although he was heavily influenced by several uncles who were physicians, including one oncologist. After completing his medical training at the University of Colorado, he chose community oncology over academia because he wanted to remain a generalist who could treat all tumor types rather than being restricted to a specific disease group. A formative rotation at Rocky Mountain Cancer Centers solidified this desire, as Dr Call noted he was impressed by the deep knowledge required to treat various cancers and the positive atmosphere of outpatient care.
Immuno-Oncology and Novel Cell Therapies Set Transformation in Motion for Gynecologic Oncology: With Ursula A. Matulonis, MD; and Rebecca Porter, MD, PhD
In this episode, Dr Matulonis sat down with guest Rebecca Porter, MD, PhD. Dr Porter is a physician at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School. Drs Matulonis and Porter discussed the evolving role of immunotherapy in gynecologic cancer management, focusing on recent clinical breakthroughs and future directions. They noted that although high-grade serous ovarian cancer has historically been refractory to immunotherapy, the phase 3 KEYNOTE-B96 trial (NCT05116189) demonstrated an efficacy benefit with the addition of pembrolizumab to weekly paclitaxel for patients with platinum-resistant disease. In particular, improvements in overall survival were noted in the PD-L1–positive patient population. Dr Porter attributed this success to the metronomic weekly dosing of paclitaxel, which may increase neoantigen levels and favorably alter the tumor microenvironment (TME).
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
In this episode, we welcomed John O. Mascarenhas, MD, a member of The Tisch Cancer Institute, a professor of medicine at the Icahn School of Medicine, and director of the Center of Excellence for Blood Cancers and Myeloid Disorders at Mount Sinai in New York, New York. In the exclusive interview, Dr Mascarenhas explored novel targeted therapeutic approaches being evaluated in patients with myeloproliferative neoplasms, including myelofibrosis and polycythemia vera. He outlined key reasons for investigating non–JAK inhibitor agents within this treatment paradigm; outlined data from a pair of phase 1 trials (NCT05936359; NCT06034002) evaluating INCA033989 as monotherapy or in combination with ruxolitinib (Jakafi) in patients with CALR exon 9–mutated myelofibrosis; detailed an ongoing phase 1 study (NCT06313593) looking at INCB160058 in patients with MPNs; and explained how investigational targeted therapies could ultimately impact the MPN treatment paradigm.
ELEGANT Trial Seeks to Expand Treatment Options for ER+, HER2-Negative Early Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
In this episode, the discussion features Aditya Bardia, MD, MPH, FASCO. Dr Bardia is a professor in the Department of Medicine in the Division of Hematology/Oncology, the director of Translational Research Integration, and a member of Signal Transduction and Therapeutics at the UCLA Health Jonsson Comprehensive Cancer Center in Los Angeles, California. In the exclusive interview, Dr Bardia discussed the rationale and design of the phase 3 ELEGANT study (NCT06492616), which is evaluating elacestrant (Orserdu) compared with standard endocrine therapy in patients with estrogen receptor–positive, HER2-negative early breast cancer at high risk of disease recurrence.
Multidisciplinary Breast Cancer Experts Outline Proactive Strategies for Managing Treatment-Related Toxicities: With Neil Iyengar, MD; Heather Moore, CPP, PharmD; and Sarah Donahue, MPH, NP
In this episode, Neil Iyengar, MD, moderated an OncLive Insights discussion about adverse effect management when using breast cancer therapies targeting the PI3K, AKT, and mTOR pathways. Dr Iyengar is an associate professor in the Department of Hematology and Medical Oncology and co-director of Breast Medical Oncology in the Department of Hematology and Medical Oncology at Emory University School of Medicine; as well as director of Survivorship Services at the Winship Cancer Institute of Emory University in Atlanta, Georgia. He was joined by Heather Moore, CPP, PharmD, a clinical pharmacist practitioner at the Duke Cancer Center Breast Clinic in Durham, North Carolina; and Sarah Donahue, MPH, NP, a nurse practitioner at the University of California, San Francisco Health. In their exclusive discussion, the experts highlighted the importance of early and comprehensive testing (using both tissue and liquid biopsies) for genetic alterations to guide treatment decisions. They also noted strategies for managing diarrhea, including patient education on diet, proactive use of loperamide, and regular monitoring.
Long-Term Epcoritamab Data Show Durable Responses and Confirmed Safety in LBCL: With Tycel Phillips, MD
In this episode, our discussion features Tycel Phillips, MD. Dr Phillips is an associate professor in the Department of Hematology and Hematopoietic Cell Transplantation in the Division of Lymphoma at City of Hope in Duarte, California. In our exclusive interview, Dr Phillips discussed updated efficacy and safety data from the phase 2 EPCORE NHL-1 trial (NCT03625037) investigating epcoritamab-bysp (Epkinly) monotherapy in patients with relapsed/refractory large B-cell lymphoma (LBCL). He noted that the data, which were presented at the 2025 ASH Annual Meeting, showed that several patients remained in response beyond 4 years, and that no new major safety signals were reported. He highlighted that the trial findings continue to support the use of epcoritamab as a third-line, potentially curative option for patients with LBCL. He also spotlighted the promise of synergistic polatuzumab vedotin-piiq (Polivy)–based combinations in the management of non-Hodgkin lymphoma.
Multimodality in Oncology: Are We There Yet?
In this episode, the discussion features Philippe Menu, MD, PhD, MBA. Dr Menu is executive vice president, chief product officer, and chief medical officer at SOPHiA GENETICS. In this thought leadership conversation, Dr Menu is joined by Pedram Razavi, MD, PhD, a breast medical oncologist and director of the Liquid Biopsy and Cancer Genomics, MSK Biomarker Development Program at Memorial Sloan Kettering Cancer Center, and Matthew Lungren, MD, MPH, a professor of clinical AI at Stanford University and health technology leader at Microsoft.
In the interview, the panel offers a practical assessment of where multimodality stands today in oncology, emphasizing that although it is frequently positioned as a key next step for cancer care, its integration into routine clinical workflows remains uneven and operationally complex. Dr Razavi provides a clinician’s perspective on real-world implementation constraints and how multimodal inputs translate into day-to-day decision-making in a high-volume cancer center, while Dr Lungren discusses the AI and data infrastructure requirements needed to support scalable deployment across health systems.
Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Ailawadhi, MD; and Beth Faiman, CNP, PhD
In this episode, the discussion features Sikander Ailawadhi, MD, and Beth Faiman, CNP, PhD, who provided clinical perspectives on the ongoing development of subcutaneous isatuximab-irfc (Sarclisa) administration via an on-body injector for patients with multiple myeloma. Dr Ailawadhi is a professor of medicine, a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, and a consultant in the Department of Cancer Biology at the Mayo Clinic Comprehensive Cancer Center in Jacksonville, Florida. Dr Faiman is a nurse practitioner in the Department of Hematology/Oncology at Cleveland Clinic and a member of the Cancer Prevention, Control and Population Research Program at the Case Comprehensive Cancer Center, both in Cleveland, Ohio. Drs Ailawadhi and Faiman reviewed findings from the phase 3 IRAKLIA study (NCT05405166), which showed that subcutaneous isatuximab delivered with an on-body injector was noninferior to intravenous isatuximab regarding efficacy, including overall response rate; pharmacokinetics; and toxicity profiles, alongside higher patient satisfaction rates.
Early, Reflex Biomarker Testing Is Critical to Optimizing NSCLC Treatment Decisions Across Disease Stages: With Adam Fox, MD, and Cynthia A. Schandl, MD, PhD
In this episode, the discussion features Adam Fox, MD, an assistant professor in the Department of Medicine at the College of Medicine at the Medical University of South Carolina in Charleston, and Cynthia A. Schandl, MD, PhD, medical director of clinical laboratories and director of the Division of Clinical Pathology in the College of Medicine at the Medical University of South Carolina, who examined the expanding role of biomarker testing and genomic profiling in non–small cell lung cancer (NSCLC) across disease stages. In the interview, Dr Fox and Dr Schandl emphasized that comprehensive biomarker testing has become increasingly essential at the time of diagnosis in metastatic disease, as well as in earlier-stage NSCLC, where results can directly influence neoadjuvant and adjuvant treatment decisions.
Expanded BTK Inhibitor Research Directs the Evolution of Pirtobrutinib Use in CLL: With Andrew Lipsky, MD
In this episode, Andrew Lipsky, MD, reviewed recent updates with BTK inhibitors in the chronic lymphocytic leukemia (CLL) treatment paradigm, including the clinical significance of the December 2025 FDA approval of pirtobrutinib (Jaypirca) in relapsed/refractory CLL and its effect on sequencing decisions for this disease. Dr Lipsky is an assistant professor of medicine at the Columbia University Medical Center in New York, New York. Dr Lipsky expanded on the positioning of this agent within the evolving CLL treatment paradigm and patient characteristics that may inform its use in practice; key efficacy and safety findings from a pooled analysis of the phase 3 BRUIN CLL-321 (NCT04666038) and phase 1/2 BRUIN LOXO-BTK-18001 (NCT03740529) studies presented during the 2025 ASH Annual Meeting; and the evolving role of BTK inhibitors as a whole in CLL management.
ASCENT-07 Trial Propels Further Questions About the Role of Earlier-Line ADCs in HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP
In this episode, the discussion features Komal Jhaveri, MD, FACP, a breast medical oncologist at Memorial Sloan Kettering Cancer Center, who reviewed the evolving role of TROP2-directed antibody–drug conjugates (ADCs) in the management of hormone receptor (HR)–positive, HER2-negative metastatic breast cancer. She drew on findings from the phase 3 ASCENT-07 trial (NCT05840211), which evaluated sacituzumab govitecan-hziy (Trodelvy) in the first-line setting following endocrine therapy for patients with HR-positive, HER2-negative metastatic breast cancer. Dr Jhaveri discussed the rationale for evaluating sacituzumab govitecan earlier in the treatment paradigm, summarized key efficacy outcomes from ASCENT-07, and contextualized why the trial did not meet its primary progression-free survival end point. She also highlighted how disease biology and patient selection may influence outcomes when ADCs are moved into earlier lines of therapy, and outlined practical considerations for toxicity management and future trial design as the TROP2 ADC landscape continues to evolve.
Multidisciplinary Teams Optimize Surgical and Therapeutic Roles in Advanced CSCC Care: With Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS
In this episode, our discussion features Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS. Dr Whitman is medical director of the oncology service line with Atlantic Health System in Morristown, New Jersey. Dr Patel is an associate professor of dermatology and medicine at the GW School of Medicine & Health Sciences, as well as the director of the Cutaneous Oncology Program at the GW Cancer Center in Washington, DC. Drs Whitman and Patel discussed the evolving treatment paradigm for patients with cutaneous squamous cell carcinoma (CSCC), emphasizing the role of neoadjuvant and adjuvant immunotherapies like cemiplimab and pembrolizumab.
